APAC IPOs & Placements, Aequitas Research

Ethan Aw

At Aequitas we cover all IPOs and placements across Asia-Pac with a deal size of at least US$100m. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

APAC IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

MicroPort Cardiac Rhythm Management / Equity Capital Markets

MicroPort Cardiac Rhythm Management (1813053D CH)

<ul>
<li>
<a href="https://www.smartkarma.com/entities/microport-cardiac-rhythm-management" target="_blank" data-smartkarma-citation="entities:39809:1" rel="noopener">MicroPort Cardiac Rhythm Management (1813053D CH)</a> is looking to raise about US$200m in its upcoming HK IPO. The deal will be run by Goldman Sachs and CICC.</li>
<li>Microport Cardiac Rhythm Management (MCRM) is a R&amp;D-driven, commercial-stage medical technology company specializing in active implantable medical devices for cardiac rhythm management (CRM). </li>
<li>Its operations are dedicated to the design, development and commercialization of products and solutions to treat and manage arrhythmias and heart failure. </li>
</ul>



MicroPort Cardiac Rhythm Management (1813053D CH) is looking to raise about US$200m in its upcoming HK IPO. The deal will be run by Goldman Sachs and CICC.
Microport Cardiac Rhythm Management (MCRM) is a R&amp;D-driven, commercial-stage medical technology company specializing in active implantable medical devices for cardiac rhythm management (CRM). 
Its operations are dedicated to the design, development and commercialization of products and solutions to treat and manage arrhythmias and heart failure. 


Microport Cardiac Rhythm Management Pre-IPO Tearsheet